Inhibikase TherapeuticsIKT +3.80%28 EBIT per Share is $-0.48 as of Mar. 2026. GuruFocus rates IKT with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,172 Biotechnology companies, Inhibikase Therapeutics ranks better than 85.84% on this metric.
Inhibikase Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.11.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.48.
During the past 3 years, the average EBIT per Share Growth Rate was 49.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 27.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Inhibikase Therapeutics's EBIT per Share or its related term are showing as below:
IKT'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -56.5 Med: -8 Max: 49.8
Current: 49.8
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Inhibikase Therapeutics was 49.80% per year. The lowest was -56.50% per year. And the median was -8.00% per year.
IKT's 3-Year EBIT Growth Rate is ranked better than 85.84% of 1172
companies
in the Biotechnology industry
Industry Median: 15.35
vs IKT: 49.80
Inhibikase Therapeutics (NAS:IKT) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Inhibikase Therapeutics EBIT per Share Related Terms
Inhibikase Therapeutics EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibikase Therapeutics (IKT) has a EBIT per Share of $-0.48 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Inhibikase Therapeutics and its competitors. According to the industry distribution chart, Inhibikase Therapeutics ranks #166 out of 1172 companies in the Biotechnology industry, placing it in the top 14.2%.
Is Inhibikase Therapeutics' EBIT per Share too high?
Inhibikase Therapeutics' current EBIT per Share is $-0.48. Based on the distribution chart, Inhibikase Therapeutics ranks #166 out of 1172 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Inhibikase Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' EBIT per Share compare to FHTX and OBIO?
According to the Biotechnology industry distribution chart, Inhibikase Therapeutics ranks #166 out of 1172 companies for EBIT per Share. This places Inhibikase Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Inhibikase Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inhibikase Therapeutics's current EBIT per Share is $-0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current EBIT per Share of $-0.48. The current EBIT per Share is $-0.48. Inhibikase Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current EBIT per Share is $-0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
28GF Score
Get the complete analysis for IKT
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IKT has been successfully added to your 
